Alejandro Alvaro-Meca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7810611/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiological trend of hospitalized acute and recurrent hepatitis C in Spain. Annals of Medicine, 2024, 51, 68-68.	3.8	0
2	Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain. Open Forum Infectious Diseases, 2021, 8, ofab251.	0.9	0
3	Spatio-Temporal Traffic Flow Prediction in Madrid: An Application of Residual Convolutional Neural Networks. Mathematics, 2021, 9, 1068.	2.2	5
4	Modelling Interaction Effects by Using Extended WOE Variables with Applications to Credit Scoring. Mathematics, 2021, 9, 1903.	2.2	1
5	Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, , 1-8.	1.2	1
6	Reliability and discriminative validity of real-time ultrasound elastography in the assessment of tissue stiffness after calf muscle injury. Journal of Bodywork and Movement Therapies, 2021, 28, 463-469.	1.2	3
7	Environmental factors are associated with hospital admissions for sepsis-related pneumonia: A bidirectional case-crossover design. Environmental Research, 2020, 191, 110102.	7.5	4
8	Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000–2015): A Nationwide Study. Journal of Clinical Medicine, 2020, 9, 1607.	2.4	2
9	Epidemiological trend of hepatitis C-related liver events in Spain (2000–2015): A nationwide population-based study. European Journal of Internal Medicine, 2020, 75, 84-92.	2.2	7
10	Gender-based vulnerability in women who inject drugs in a harm reduction setting. PLoS ONE, 2020, 15, e0230886.	2.5	20
11	National Temporal Trend Analysis of Infective Endocarditis among Patients Infected with HIV in Spain (1997–2014): A Retrospective Study. Journal of Clinical Medicine, 2019, 8, 1167.	2.4	4
12	High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. International Journal of Drug Policy, 2019, 72, 181-188.	3.3	29
13	Analysis of environmental risk factors for chronic obstructive pulmonary disease exacerbation: A case-crossover study (2004-2013). PLoS ONE, 2019, 14, e0217143.	2.5	33
14	High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit. Aids, 2018, 32, 1157-1163.	2.2	3
15	Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997–2013): A nationwide population-based study in Spain. European Journal of Internal Medicine, 2018, 48, 69-74.	2.2	3
16	Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study. Scientific Reports, 2018, 8, 12137.	3.3	4
17	HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination. PLoS ONE, 2018, 13, e0204795.	2.5	10
18	Epidemiological trends of sepsis in the twenty-first century (2000–2013): an analysis of incidence, mortality, and associated costs in Spain. Population Health Metrics, 2018, 16, 4.	2.7	51

#	Article	IF	CITATIONS
19	Adverse drug reactions to anticoagulants in Spain: analysis of the Spanish National Hospital Discharge Data (2010–2013). BMJ Open, 2017, 7, e013224.	1.9	10
20	Prediction of in-hospital mortality after pancreatic resection in pancreatic cancer patients: A boosting approach via a population-based study using health administrative data. PLoS ONE, 2017, 12, e0178757.	2.5	17
21	Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era. PLoS ONE, 2017, 12, e0179493.	2.5	14
22	Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study. International Journal of Environmental Research and Public Health, 2016, 13, 1177.	2.6	15
23	Environmental Factors Related to Pulmonary Tuberculosis in HIV-Infected Patients in the Combined Antiretroviral Therapy (cART) Era. PLoS ONE, 2016, 11, e0165944.	2.5	34
24	Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997–2012). PLoS ONE, 2016, 11, e0166421.	2.5	11
25	Predictors of in-hospital mortality following major lower extremity amputations in type 2 diabetic patients using artificial neural networks. BMC Medical Research Methodology, 2016, 16, 160.	3.1	13
26	Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study. Human Vaccines and Immunotherapeutics, 2016, 12, 1-6.	3.3	31
27	Analysis of environmental risk factors for pulmonary embolism: A case-crossover study (2001–2013). European Journal of Internal Medicine, 2016, 31, 55-61.	2.2	16
28	Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit. BMC Infectious Diseases, 2016, 16, 122.	2.9	5
29	Fifteen-Year Trends in the Prevalence of Diabetes among Hospitalized HIV-Infected Patients in Spain (1997-2012). PLoS ONE, 2016, 11, e0161953.	2.5	3
30	NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. PLoS ONE, 2016, 11, e0163197.	2.5	16
31	Epidemiology of hospitalizations caused by mumps in the general population in Spain (1997–2006). Journal of Pediatric Infectious Diseases, 2015, 06, 177-183.	0.2	0
32	Trends in nontuberculous mycobacterial disease in hospitalized subjects in <scp>S</scp> pain (1997–2010) according to <scp>HIV</scp> infection. HIV Medicine, 2015, 16, 485-493.	2.2	8
33	Time trends in coronary revascularization procedures among people with COPD: analysis of the Spanish national hospital discharge data (2001–2011). International Journal of COPD, 2015, 10, 2285.	2.3	5
34	<i>Pneumocystis</i> pneumonia in HIVâ€positive patients in Spain: epidemiology and environmental risk factors. Journal of the International AIDS Society, 2015, 18, 19906.	3.0	23
35	Time Trends in Ischemic Stroke among Type 2 Diabetic and Non-Diabetic Patients: Analysis of the Spanish National Hospital Discharge Data (2003-2012). PLoS ONE, 2015, 10, e0145535.	2.5	33
36	Epidemiology of hospitalizations caused by measles in the general population in Spain (1997–2006). Journal of Pediatric Infectious Diseases, 2015, 05, 131-137.	0.2	0

#	Article	IF	CITATIONS
37	Evaluation of Conjunctival Bleb Detection After Vitrectomy by Ultrasound Biomicroscopy, Optical Coherence Tomography and Direct Visualization. Current Eye Research, 2014, 39, 390-394.	1.5	6
38	Incidence and mortality of tuberculosis disease in Spain between 1997 and 2010: Impact of human immunodeficiency virus (HIV) status. Journal of Infection, 2014, 68, 355-362.	3.3	12
39	Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997–2008). BMC Infectious Diseases, 2013, 13, 115.	2.9	7
40	Impact of non-routine rotavirus vaccination on hospitalizations for diarrhoea and rotavirus infections in Spain. Vaccine, 2013, 31, 5000-5004.	3.8	21
41	Epidemiology of suicide in Spain, 1981–2008: AÂspatiotemporal analysis. Public Health, 2013, 127, 380-385.	2.9	35
42	Factors involved in health-related transitions after curative resection for pancreatic cancer. 10-Years experience: A multi state model. Cancer Epidemiology, 2013, 37, 91-96.	1.9	7
43	Influence of Incisional Vitreous Incarceration in Sclerotomy Closure Competency After Transconjunctival Sutureless Vitrectomy. , 2013, 54, 4366.		10
44	The burden of hospitalizations for head and neck neoplasm in Spain (1997-2008): An epidemiologic study Human Vaccines and Immunotherapeutics, 2012, 8, 788-798.	3.3	4
45	The burden of hospitalizations for anus and penis neoplasm in Spain (1997–2008). Human Vaccines and Immunotherapeutics, 2012, 8, 201-207.	3.3	9
46	Trend of Pneumonia Incidence Among Children Infected With HIV in the Era of Highly Active Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2012, 31, 599-601.	2.0	3
47	Reduction in Mycobacterial Disease Among HIV-infected Children in the Highly Active Antiretroviral Therapy Era (1997–2008). Pediatric Infectious Disease Journal, 2012, 31, 278-283.	2.0	15
48	Breast cancer mortality in Spain: Has it really declined for all age groups?. Public Health, 2012, 126, 891-895.	2.9	7
49	Impact of comorbidities and surgery on health related transitions in pancreatic cancer admissions: A multi state model. Cancer Epidemiology, 2012, 36, e142-e146.	1.9	4
50	Epidemiology of gonorrhoea-related hospitalisations in Spain between 1997 and 2006. Sexual and Reproductive Healthcare, 2012, 3, 89-92.	1.2	3
51	The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003–2007). Vaccine, 2011, 29, 412-416.	3.8	66
52	The burden of hospitalizations for meningococcal infection in Spain (1997–2008). Vaccine, 2011, 29, 5765-5770.	3.8	28
53	Epidemiologic Trends of Cancer Diagnoses Among HIV-infected Children in Spain From 1997 to 2008. Pediatric Infectious Disease Journal, 2011, 30, 764-768.	2.0	21
54	Epidemiology of syphilis-related hospitalisations in Spain between 1997 and 2006: a retrospective study. BMJ Open, 2011, 1, e000270-e000270.	1.9	3

#	Article	IF	CITATIONS
55	Hospital-acquired rotavirus infections in Spain over a ten-year period (1998-2007). Hum Vaccin, 2009, 5, 748-753.	2.4	12
56	Hospitalizations associated with rotavirus gastroenteritis in Spain, 2001–2005. BMC Public Health, 2008, 8, 109.	2.9	36
57	LOW IMMUNOLOGIC RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN NAIVE VERTICALLY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED CHILDREN WITH SEVERE IMMUNODEFICIENCY. Pediatric Infectious Disease Journal, 2006, 25, 365-368.	2.0	15
58	Lopinavir/r versus Nelfinavir as Salvage Therapy. Pediatric Infectious Disease Journal, 2005, 24, 392-393.	2.0	1